Search Results - "Wolff, Robert A"

A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID‐19) Pandemic: An International Collaborative Group by Al‐Shamsi, Humaid O., Alhazzani, Waleed, Alhuraiji, Ahmad, Coomes, Eric A., Chemaly, Roy F., Almuhanna, Meshari, Wolff, Robert A., Ibrahim, Nuhad K., Chua, Melvin L.K., Hotte, Sebastien J., Meyers, Brandon M., Elfiki, Tarek, Curigliano, Giuseppe, Eng, Cathy, Grothey, Axel, Xie, Conghua

“…The outbreak of coronavirus disease 2019 (COVID‐19) has rapidly spread globally since being identified as a public health emergency of major international…”
Get full text

Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications by Churi, Chaitanya R, Shroff, Rachna, Wang, Ying, Rashid, Asif, Kang, HyunSeon C, Weatherly, Jacqueline, Zuo, Mingxin, Zinner, Ralph, Hong, David, Meric-Bernstam, Funda, Janku, Filip, Crane, Christopher H, Mishra, Lopa, Vauthey, Jean-Nicholas, Wolff, Robert A, Mills, Gordon, Javle, Milind

“…Cholangiocarcinoma (CCA) is clinically heterogeneous; intra and extrahepatic CCA have diverse clinical presentations. Next generation sequencing (NGS)…”
Get full text

Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation by Krishnan, Sunil, MD, Chadha, Awalpreet S., MD, Suh, Yelin, PhD, Chen, Hsiang-Chun, PhD, Rao, Arvind, PhD, Das, Prajnan, MD, Minsky, Bruce D., MD, Mahmood, Usama, MD, Delclos, Marc E., MD, Sawakuchi, Gabriel O., PhD, Beddar, Sam, PhD, Katz, Matthew H., MD, Fleming, Jason B., MD, Javle, Milind M., MD, Varadhachary, Gauri R., MD, Wolff, Robert A., MD, Crane, Christopher H., MD

“…Purpose To review outcomes of locally advanced pancreatic cancer (LAPC) patients treated with dose-escalated intensity modulated radiation therapy (IMRT) with…”
Get full text

Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer by Dhillon, Navneet, Aggarwal, Bharat B, Newman, Robert A, Wolff, Robert A, Kunnumakkara, Ajaikumar B, Abbruzzese, James L, Ng, Chaan S, Badmaev, Vladimir, Kurzrock, Razelle

“…Purpose: Pancreatic cancer is almost always lethal, and the only U.S. Food and Drug Administration–approved therapies for it, gemcitabine and erlotinib,…”
Get full text

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group by Moore, Malcolm J, Goldstein, David, Hamm, John, Figer, Arie, Hecht, Joel R, Gallinger, Steven, Au, Heather J, Murawa, Pawel, Walde, David, Wolff, Robert A, Campos, Daniel, Lim, Robert, Ding, Keyue, Clark, Gary, Voskoglou-Nomikos, Theodora, Ptasynski, Mieke, Parulekar, Wendy

“…Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996…”
Get full text

Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study by YAO, James C, PHAN, Alexandria T, MERIC-BERNSTAM, Funda, CHANG, David Z, WOLFF, Robert A, HESS, Kenneth, GUPTA, Sanjay, JACOBS, Carmen, MARES, Jeannette E, LANDGRAF, Andrea N, RASHID, Asif

“…Evaluate the activity of everolimus (RAD001) in combination with octreotide long-acting repeatable (LAR) in patients with advanced low- to intermediate-grade…”
Get full text

Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival by Lee, Sun Mi, Katz, Matthew H.G, Liu, Li, Sundar, Manonmani, Wang, Hua, Varadhachary, Gauri R, Wolff, Robert A, Lee, Jeffrey E, Maitra, Anirban, Fleming, Jason B, Rashid, Asif, Wang, Huamin

“…Neoadjuvant therapy has been increasingly used to treat patients with potentially resectable pancreatic ductal adenocarcinoma (PDAC). Although the College of…”
Get full text

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance by KOPETZ, Scott, HOFF, Paulo M, LIEU, Christopher, SHAOYU YAN, TRAN, Hai T, ELLIS, Lee M, ABBRUZZESE, James L, HEYMACH, John V, MORRIS, Jeffrey S, WOLFF, Robert A, ENG, Cathy, GLOVER, Katrina Y, ADININ, Rosie, OVERMAN, Michael J, VALERO, Vincete, SIJIN WEN

“…We investigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and bevacizumab (FOLFIRI + B) in a phase II trial in patients previously untreated…”
Get full text

Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression by CRANE, Christopher H, VARADHACHARY, Gauri R, DAS, Prajnan, LEE, Jeffrey E, ABBRUZZESE, James L, WOLFF, Robert A, YORDY, John S, STAERKEL, Gregg A, JAVLE, Milind M, SAFRAN, Howard, HAQUE, Waqar, HOBBS, Bridgett D, KRISHNAN, Sunil, FLEMING, Jason B

“…This phase II trial was designed to assess the efficacy and safety of cetuximab, gemcitabine, and oxaliplatin followed by cetuximab, capecitabine, and…”
Get full text

Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet by Luo, Yongde, Yang, Yaying, Liu, Muyun, Wang, Dan, Wang, Feng, Bi, Yawei, Ji, Juntao, Li, Suyun, Liu, Yan, Chen, Rong, Huang, Haojie, Wang, Xiaojie, Swidnicka-Siergiejko, Agnieszka K., Janowitz, Tobias, Beyaz, Semir, Wang, Guoqiang, Xu, Sulan, Bialkowska, Agnieszka B., Luo, Catherine K., Pin, Christoph L., Liang, Guang, Lu, Xiongbin, Wu, Maoxin, Shroyer, Kenneth R., Wolff, Robert A., Plunkett, William, Ji, Baoan, Li, Zhaoshen, Li, Ellen, Li, Xiaokun, Yang, Vincent W., Logsdon, Craig D., Abbruzzese, James L., Lu, Weiqin

“…Obesity is a risk factor for pancreatic cancer. In mice, a high-fat diet (HFD) and expression of oncogenic KRAS lead to development of invasive pancreatic…”
Get full text

HER2/neu-directed therapy for biliary tract cancer by Javle, Milind, Churi, Chaitanya, Kang, HyunSeon C, Shroff, Rachna, Janku, Filip, Surapaneni, Rakesh, Zuo, Mingxin, Barrera, Christian, Alshamsi, Humaid, Krishnan, Sunil, Mishra, Lopa, Wolff, Robert A, Kaseb, Ahmed O, Thomas, Melanie B, Siegel, Abby B

“…Biliary cancers are highly aggressive tumors that are often diagnosed an advanced disease stage and have a poor outcome with systemic therapy. Recent efforts…”
Get full text

PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors by MERIC-BERNSTAM, Funda, AKCAKANAT, Argun, PHAN, Alexandria T, WOLFF, Robert A, GUPTA, Sanjay, MILLS, Gordon B, YAO, James, HUIQIN CHEN, DO, Kim-Anh, SANGAI, Takafumi, ADKINS, Farrell, GONZALEZ-ANGULO, Ana Maria, RASHID, Asif, CROSBY, Katherine, MEI DONG

“…We sought to determine whether phosphoinositide 3-kinase (PI3K) pathway mutation or activation state and rapamycin-induced feedback loop activation of Akt is…”
Get full text

Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA by Kaseb, Ahmed O, Sánchez, Nora S, Sen, Shiraj, Kelley, Robin K, Tan, Benjamin, Bocobo, Andrea G, Lim, Kian H, Abdel-Wahab, Reham, Uemura, Marc, Pestana, Roberto Carmagnani, Qiao, Wei, Xiao, Lianchun, Morris, Jeffrey, Amin, Hesham M, Hassan, Manal M, Rashid, Asif, Banks, Kimberly C, Lanman, Richard B, Talasaz, AmirAli, Mills-Shaw, Kenna R, George, Bhawana, Haque, Abedul, Raghav, Kanwal P S, Wolff, Robert A, Yao, James C, Meric-Bernstam, Funda, Ikeda, Sadakatsu, Kurzrock, Razelle

“…Molecular profiling has been used to select patients for targeted therapy and determine prognosis. Noninvasive strategies are critical to hepatocellular…”
Get full text

Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases by BLAZER, Dan G, KISHI, Yoji, ZORZI, Daria, RIBERO, Dario, ELLIS, Lee M, GLOVER, Katrina Y, WOLFF, Robert A, CURLEY, Steven A, ABDALLA, Eddie K, VAUTHEY, Jean-Nicolas, MARU, Dipen M, KOPETZ, Scott, YUN SHIN CHUN, OVERMAN, Michael J, FOGELMAN, David, ENG, Cathy, CHANG, David Z, HUAMIN WANG

“…The primary goal of this study was to evaluate whether pathologic response to chemotherapy predicts patient survival after preoperative chemotherapy and…”
Get full text

Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement by Abrams, Ross A., Lowy, Andrew M., O’Reilly, Eileen M., Wolff, Robert A., Picozzi, Vincent J., Pisters, Peter W. T.

Get full text

Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head by EVANS, Douglas B, VARADHACHARY, Gauri R, CHARNSANGAVEJ, Chusilp, LANO, Elizabeth A, HO, Linus, LENZI, Renato, ABBRUZZESE, James L, WOLFF, Robert A, CRANE, Christopher H, SUN, Charlotte C, LEE, Jeffrey E, PISTERS, Peter W. T, VAUTHEY, Jean-Nicolas, HUAMIN WANG, CLEARY, Karen R, STAERKEL, Gregg A

“…We conducted a phase II trial to assess the outcomes of patients who received preoperative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD)…”
Get full text

Survival improvement for patients with metastatic colorectal cancer over twenty years by Zeineddine, Fadl A., Zeineddine, Mohammad A., Yousef, Abdelrahman, Gu, Yue, Chowdhury, Saikat, Dasari, Arvind, Huey, Ryan W., Johnson, Benny, Kee, Bryan, Lee, Michael S., Morelli, Maria Pia, Morris, Van K., Overman, Michael J., Parseghian, Christine, Raghav, Kanwal, Willis, Jason, Wolff, Robert A., Kawaguchi, Yoshikuni, Vauthey, Jean-Nicolas, Sun, Ryan, Kopetz, Scott, Shen, John Paul

“…Over the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and experimental…”
Get full text

Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival by Tzeng, Ching-Wei D., Cao, Hop S. Tran, Lee, Jeffrey E., Pisters, Peter W. T., Varadhachary, Gauri R., Wolff, Robert A., Abbruzzese, James L., Crane, Christopher H., Evans, Douglas B., Wang, Huamin, Abbott, Daniel E., Vauthey, Jean-Nicolas, Aloia, Thomas A., Fleming, Jason B., Katz, Matthew H. G.

“…Barriers to multimodality therapy (MMT) completion among patients with resectable pancreatic adenocarcinoma include early cancer progression and postoperative…”
Get full text

Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease by Katz, Matthew H.G., MD, Pisters, Peter W.T., MD, FACS, Evans, Douglas B., MD, FACS, Sun, Charlotte C., DrPH, MPH, Lee, Jeffrey E., MD, FACS, Fleming, Jason B., MD, FACS, Vauthey, J. Nicolas, MD, FACS, Abdalla, Eddie K., MD, FACS, Crane, Christopher H., MD, Wolff, Robert A., MD, Varadhachary, Gauri R., MD, Hwang, Rosa F., MD

“…Background Patients with borderline resectable pancreatic adenocarcinoma (PA) include those with localized disease who have tumor or patient characteristics…”
Get full text

Transport properties of pancreatic cancer describe gemcitabine delivery and response by Koay, Eugene J, Truty, Mark J, Cristini, Vittorio, Thomas, Ryan M, Chen, Rong, Chatterjee, Deyali, Kang, Ya'an, Bhosale, Priya R, Tamm, Eric P, Crane, Christopher H, Javle, Milind, Katz, Matthew H, Gottumukkala, Vijaya N, Rozner, Marc A, Shen, Haifa, Lee, Jeffery E, Wang, Huamin, Chen, Yuling, Plunkett, William, Abbruzzese, James L, Wolff, Robert A, Varadhachary, Gauri R, Ferrari, Mauro, Fleming, Jason B

“…The therapeutic resistance of pancreatic ductal adenocarcinoma (PDAC) is partly ascribed to ineffective delivery of chemotherapy to cancer cells. We…”
Get full text